Company: ELV
Filing Date: 2025-09-09
Form Type: 424B3
Source: 0001193125-25-199226
Chunk: 32

Company: Elevance Health, Inc.
Filing Date: 2025-09-09
Form: 424B3
Chunk 32
---
 |  11,250,000 |
| Scotia Capital (USA) Inc.           |     | $ |   7,500,000 |     | $ |   7,500,000 |     | $ |    10,000,000 |     | $ |   5,000,000 |
| SMBC Nikko Securities America, Inc. |     | $ |   7,500,000 |     | $ |   7,500,000 |     | $ |    10,000,000 |     | $ |   5,000,000 |
| TD Securities (USA) LLC             |     | $ |   7,500,000 |     | $ |   7,500,000 |     | $ |    10,000,000 |     | $ |   5,000,000 |
| Total                               |     | $ | 750,000,000 |     | $ | 750,000,000 |     | $ | 1,000,000,000 |     | $ | 500,000,000 |

The underwriting agreement is subject to a number of terms and conditions and provides that the underwriters must buy all of the notes if they buy any of them. The underwriters will sell the notes to the public when and if the underwriters buy the notes from us. The underwriters have advised us that they propose to initially offer the notes to the public for cash at the public offering prices set forth on the cover of this prospectus supplement, and that they may offer the notes to certain dealers at such price less concessions not in excess of 0.150% of the principal amount of the 2028 notes, 0.200% of the principal amount of the 2032 notes, 0.250% of the principal amount of the 2036 notes, and 0.500% of the principal amount of the 2055 notes. The underwriters may allow, and such dealers may reallow, a concession not in excess of 0.100% of the principal amount of the 2028 notes, 0.150% of the principal amount of the 2032 notes, 0.200% of the principal amount of the 2036 notes, and 0.350% of the principal amount of the 2055 notes to certain other dealers. After the public offering of the notes, the public offering prices and other selling terms may be